Viridian Therapeutics, Inc. (VRDN)
| Market Cap | 382.61M |
| Revenue (ttm) | 1.73M |
| Net Income (ttm) | -86.65M |
| Shares Out | 27.93M |
| EPS (ttm) | -5.14 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 453,634 |
| Open | 13.70 |
| Previous Close | 13.64 |
| Day's Range | 13.45 - 14.33 |
| 52-Week Range | 9.47 - 22.00 |
| Beta | 1.18 |
| Analysts | Buy |
| Price Target | 33.77 (+146.5%) |
| Earnings Date | Aug 15, 2022 |
About VRDN
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viri... [Read more...]
Financial Performance
In 2021, VRDN's revenue was $2.96 million, an increase of 182.19% compared to the previous year's $1.05 million. Losses were -$79.41 million, -28.27% less than in 2020.
Financial StatementsAnalyst Forecast
According to 15 analysts, the average rating for VRDN stock is "Buy." The 12-month stock price forecast is 33.77, which is an increase of 146.50% from the latest price.
News
Viridian Therapeutics to Report Second Quarter 2022 Financial Results and Host Conference Call on August 15, 2022
WALTHAM, Mass., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by...
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass., Aug. 05, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (Nasdaq: VRDN) (the “Company” or “Viridian”), a biotechnology company advancing new treatments for patients suffering from s...
INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Viridian Therapeutics, Inc. with Losses to Contact ...
Los Angeles, California--(Newsfile Corp. - June 24, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Viridi...
Viridian Therapeutics Appoints Carrie Melvin as Chief Operating Officer
WALTHAM, Mass., June 23, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by...
Viridian Therapeutics to Participate in June Investor Conferences
WALTHAM, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by...
Viridian Therapeutics, Inc. (VRDN) Reports Q1 Loss, Lags Revenue Estimates
Viridian Therapeutics, Inc. (VRDN) delivered earnings and revenue surprises of -6.52% and 66.77%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Viridian Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Updates
-- Phase 1/2 clinical trial for VRDN-001 currently recruiting Thyroid Eye Disease (TED) patients at sites in the U.S. and Canada; top line proof of concept data expected in the third quarter of 2022 -- ...
Viridian Therapeutics to Report First Quarter 2022 Financial Results and Host Conference Call on May 12, 2022
WALTHAM, Mass., May 03, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by ...
Viridian Therapeutics to Participate in The 21st Annual Needham Virtual Healthcare Conference on April 14
WALTHAM, Mass., April 06, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases underserved b...
Viridian Therapeutics Secures Flexible Credit Facility for Up to $75 Million From Hercules Capital
WALTHAM, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases underserved b...
Viridian Therapeutics Doses First Subject in First-in-Human Clinical Trial Evaluating VRDN-002, a Next Generation IGF...
- VRDN-002 incorporates clinically validated half-life extension technology to support development as a low volume subcutaneous injection that could broaden settings of care -
Viridian Therapeutics to Participate in 32nd Annual Oppenheimer Healthcare Conference on March 15
WALTHAM, Mass., March 14, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases underserved b...
Viridian Therapeutics Reports Fourth Quarter And Full Year 2021 Financial Results And Provides Corporate Updates
-- Ongoing Phase 1/2 clinical trial for VRDN-001, an IGF-1R antibody for the treatment of Thyroid Eye Disease, is on track to report top line proof of concept data in the second quarter of 2022 -- -- VR...
Viridian Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results and Host Investor Conference Call...
WALTHAM, Mass., March 03, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases underserved b...
Viridian Therapeutics to Participate in the SVB Leerink 2022 Global Healthcare Conference on February 18
WALTHAM, Mass., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by...
Viridian Therapeutics To Test Next-Gen IGF-1R Antibody In Thyroid Eye Disease
The FDA has signed off Viridian Therapeutics Inc's VRDN investigational new drug (IND) application of VRDN-002. [ALERT] Nic Chahine shares his Bear Market Beating options trading strategy.
Viridian Therapeutics Announces FDA Clearance of Investigational New Drug Application to Initiate Clinical Developmen...
- VRDN-002 incorporates clinically validated half-life extension technology to support development as a low volume subcutaneous injection - - Company expects to report top line VRDN-002 Phase 1 clinical...
Viridian Therapeutics Submits Investigational New Drug Application for VRDN-002 to the U.S. Food and Drug Administration
- VRDN-002 is a novel anti-IGF-1R monoclonal antibody for thyroid eye disease and incorporates half-life extension technology designed to improve dosing and administration - - Company ...
Viridian Therapeutics Announces First Subject Dosed in Phase 1/2 Clinical Trial of VRDN-001 for Thyroid Eye Disease (...
- VRDN-001 targets and blocks IGF-1R, the only mechanism of action proven to deliver efficacy in TED - - Trial is on track to deliver top line proof of concept clinical data in 2Q 2022 -
Viridian Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for VRDN-001, an IGF-1R A...
WALTHAM, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN) (the “Company” or “Viridian”), a biotechnology company advancing new treatments for patients suffering from s...
Viridian Therapeutics, Inc. (VRDN) Reports Q3 Loss, Misses Revenue Estimates
Viridian Therapeutics, Inc. (VRDN) delivered earnings and revenue surprises of -5.04% and -79.20%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for th...
Viridian Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Updates
WALTHAM, Mass, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN) (the “Company” or “Viridian”), a biotechnology company advancing new treatments for patients suffering from se...
Viridian Therapeutics to Present at Upcoming Investor Conferences
WALTHAM, Mass., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases but underserve...
Viridian Therapeutics Submits Investigational New Drug Application for VRDN-001, an IGF-1R antibody for the treatment...
- VRDN-001 program remains on track for key proof of concept clinical data in Thyroid Eye Disease patients in the second quarter of 2022 -
Viridian Therapeutics to Present Preclinical Data on VRDN-001 and VRDN-002 at the 90th Annual Meeting of the American...
WALTHAM, Mass., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company advancing new treatments for patients suffering from serious diseases but under...